Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:ARDX NASDAQ:ARWR NASDAQ:KYMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$87.99-0.3%$74.77$47.86▼$107.37$4.87B0.31634,357 shs364,262 shsARDXArdelyx$5.06-0.1%$5.86$3.21▼$6.78$1.22B0.674.49 million shs1.84 million shsARWRArrowhead Pharmaceuticals$36.04-2.4%$25.80$9.57▼$39.42$4.98B1.132.07 million shs1.17 million shsKYMRKymera Therapeutics$56.93+1.1%$46.45$19.44▼$59.00$4.07B2.26753,350 shs610,640 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+3.61%+7.63%+24.16%+28.22%+9.20%ARDXArdelyx-2.13%-5.60%-23.22%+7.66%-15.10%ARWRArrowhead Pharmaceuticals+1.09%+5.51%+35.96%+95.86%+104.99%KYMRKymera Therapeutics-1.11%+2.98%+30.12%+24.51%+30.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$87.99-0.3%$74.77$47.86▼$107.37$4.87B0.31634,357 shs364,262 shsARDXArdelyx$5.06-0.1%$5.86$3.21▼$6.78$1.22B0.674.49 million shs1.84 million shsARWRArrowhead Pharmaceuticals$36.04-2.4%$25.80$9.57▼$39.42$4.98B1.132.07 million shs1.17 million shsKYMRKymera Therapeutics$56.93+1.1%$46.45$19.44▼$59.00$4.07B2.26753,350 shs610,640 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+3.61%+7.63%+24.16%+28.22%+9.20%ARDXArdelyx-2.13%-5.60%-23.22%+7.66%-15.10%ARWRArrowhead Pharmaceuticals+1.09%+5.51%+35.96%+95.86%+104.99%KYMRKymera Therapeutics-1.11%+2.98%+30.12%+24.51%+30.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.87Moderate Buy$112.6928.70% UpsideARDXArdelyx 2.91Moderate Buy$11.70129.64% UpsideARWRArrowhead Pharmaceuticals 2.78Moderate Buy$43.1419.17% UpsideKYMRKymera Therapeutics 2.95Moderate Buy$61.267.81% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, ARWR, ACLX, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$88.0010/8/2025ACLXArcellxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ARDXArdelyxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ARWRArrowhead PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.0010/8/2025KYMRKymera TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/1/2025KYMRKymera TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $63.009/30/2025KYMRKymera TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $68.009/27/2025ACLXArcellxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ARDXArdelyxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ARWRArrowhead PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$56.98M85.23N/AN/A$8.41 per share10.41ARDXArdelyx$333.61M3.68N/AN/A$0.73 per share6.98ARWRArrowhead Pharmaceuticals$572.98M8.74N/AN/A$1.54 per share23.51KYMRKymera Therapeutics$47.07M86.32N/AN/A$12.90 per share4.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)ARDXArdelyx-$39.14M-$0.23N/A16.44N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.47N/AN/AN/A-616.03%-31.60%-27.12%10/30/2025 (Estimated)Latest ARDX, ARWR, ACLX, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ACLXArcellx-$1.00N/AN/AN/A$11.24 millionN/A10/30/2025Q3 2025ARDXArdelyx-$0.07N/AN/AN/A$100.44 millionN/A10/30/2025Q3 2025KYMRKymera Therapeutics-$0.73N/AN/AN/AN/AN/A8/11/2025Q2 2025KYMRKymera Therapeutics-$0.83-$0.95-$0.12-$0.95$17.37 million$11.48 million8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AARDXArdelyxN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81ARDXArdelyx1.444.304.03ARWRArrowhead Pharmaceuticals0.394.874.87KYMRKymera TherapeuticsN/A8.328.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ARDXArdelyx58.92%ARWRArrowhead Pharmaceuticals62.61%KYMRKymera TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx8.35%ARDXArdelyx4.80%ARWRArrowhead Pharmaceuticals4.30%KYMRKymera Therapeutics16.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableARDXArdelyx90240.98 million229.42 millionOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableKYMRKymera Therapeutics17071.50 million60.05 millionOptionableARDX, ARWR, ACLX, and KYMR HeadlinesRecent News About These CompaniesKeudell Morrison Wealth Management Invests $334,000 in Kymera Therapeutics, Inc. $KYMROctober 5, 2025 | marketbeat.comBrokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $59.95October 5, 2025 | americanbankingnews.comOppenheimer Maintains Kymera Therapeutics (KYMR) Outperform RecommendationOctober 2, 2025 | msn.comKymera Therapeutics (NASDAQ:KYMR) Sets New 52-Week High on Analyst UpgradeOctober 2, 2025 | americanbankingnews.comKymera Overcomes Sanofi Deal Update, Marches Ahead With PipelineOctober 1, 2025 | zacks.comKymera Therapeutics price target raised to $68 from $53 at TruistOctober 1, 2025 | msn.comTruist Securities Maintains Kymera Therapeutics (KYMR) Buy RecommendationOctober 1, 2025 | msn.comTruist Financial Boosts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $68.00October 1, 2025 | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High Following Analyst UpgradeOctober 1, 2025 | marketbeat.comTruist Financial Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $68.00September 30, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from AnalystsSeptember 30, 2025 | marketbeat.comKymera Therapeutics (KYMR): Revisiting Valuation After Recent Share Price MomentumSeptember 29, 2025 | finance.yahoo.comKymera Therapeutics (NASDAQ:KYMR) Reaches New 12-Month High - Time to Buy?September 25, 2025 | marketbeat.comStocks To Watch: Kymera Therapeutics Sees RS Rating Jump To 83September 25, 2025 | msn.comVoya Investment Management LLC Lowers Stock Holdings in Kymera Therapeutics, Inc. $KYMRSeptember 24, 2025 | marketbeat.comHC Wainwright Has Positive Estimate for KYMR FY2029 EarningsSeptember 22, 2025 | marketbeat.comHC Wainwright Increases Kymera Therapeutics (NASDAQ:KYMR) Price Target to $70.00September 19, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Rating Increased to Strong-Buy at BarclaysSeptember 19, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) CFO Sells $3,961,000.00 in StockSeptember 18, 2025 | marketbeat.comKymera Therapeutics price target raised to $70 from $60 at H.C. WainwrightSeptember 18, 2025 | msn.comKymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at BarclaysSeptember 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDX, ARWR, ACLX, and KYMR Company DescriptionsArcellx NASDAQ:ACLX$87.84 -0.45 (-0.51%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Ardelyx NASDAQ:ARDX$5.06 -0.01 (-0.10%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Arrowhead Pharmaceuticals NASDAQ:ARWR$36.03 -0.91 (-2.45%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Kymera Therapeutics NASDAQ:KYMR$56.96 +0.68 (+1.20%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AI Meets Nuclear: Palantir’s Role in Energy Expansion Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
